hepatocellular-carcinoma

Documents about hepatocellular-carcinoma

• Relevance of Sarcopenia in Advanced Liver Disease#889665ClinicalTrials.gov
• DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab#900625ClinicalTrials.gov
• Asian Phase I Study Of PF-03446962#904227ClinicalTrials.gov
• Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma#909973ClinicalTrials.gov
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors#146451ClinicalTrials.gov
• Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter#907167ClinicalTrials.gov
• Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis#889893ClinicalTrials.gov
• A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy#890938ClinicalTrials.gov
• Evaluate the Effect of Tirazamine on Primary Liver Cancer.#875266ClinicalTrials.gov
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy#303573ClinicalTrials.gov
• The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.#804206ClinicalTrials.gov
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence#859745ClinicalTrials.gov
• High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis#129223PMC Full-Text (OAI)
• IL4I1+ macrophages drive hepatocellular carcinoma progression by responding to biomechanical cues.#174535NCBI PubMed Central
• Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).#242237NCBI PubMed Central
• Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions#394751ClinicalTrials.gov
• Dendritic Killer Cell-based Immunotherapy for Solid Tumors#463703ClinicalTrials.gov
• Kynurenine metabolism-related gene signature for prognostic stratification in hepatocellular carcinoma.#685554NCBI PubMed Central
• Stereotactic Body Radiotherapy for Liver Tumors#842580ClinicalTrials.gov
• Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC#842887ClinicalTrials.gov
• Prospective Liver Study#856027ClinicalTrials.gov
• DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC#864322ClinicalTrials.gov
• Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy#828112ClinicalTrials.gov
• TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)#836652ClinicalTrials.gov
• A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma#853858ClinicalTrials.gov
• The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial#866723ClinicalTrials.gov
• A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery#904615ClinicalTrials.gov
• Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning#855704ClinicalTrials.gov
• A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)#883945ClinicalTrials.gov
• Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors#18589ClinicalTrials.gov
• Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.#800654ClinicalTrials.gov
• A Phase 1 Study of the Safety and Tolerability of CTX-10726#846001ClinicalTrials.gov
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors#875169ClinicalTrials.gov
• Harnessing Proteogenomics to Advance Precision Oncology: From Melanoma and Hepatocellular Carcinoma Perspective.#4330NCBI PubMed Central
• RRP9 suppresses hepatocellular carcinoma progression by inhibiting the PI3K/AKT/mTOR pathway.#143212NCBI PubMed Central
• Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma#146446ClinicalTrials.gov
• Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC#195308ClinicalTrials.gov
• Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma.#220950NCBI PubMed Central
• Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)#256885ClinicalTrials.gov
• Fractal analysis of hepatocellular carcinoma vasculature shows regional differences independent of vascular invasion#257601HAL (France)
• Antitumor effect of the AP5Z1 small-molecule inhibitor PGG in hepatocellular carcinoma.#318038NCBI PubMed Central
• High-sensitivity photoelectric sensing of apatinib for recurrent hepatocellular carcinoma in TACE.#338488NCBI PubMed Central
• PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma#389948S-Space: Seoul National University
• Licoricidin triggers reactive oxygen species-mediated PANoptosis in human hepatocellular carcinoma cells.#412349NCBI PubMed Central
• Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma#676793HAL (France)
• Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)#842976ClinicalTrials.gov
• Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis#863246ClinicalTrials.gov
• The Overall Survival of Patients With Unresectable HCC in Real-life#878835ClinicalTrials.gov
• The Application of Serum DNA Methylation for Patients With HCC#893589ClinicalTrials.gov
• Pressure-enabled Delivery in Radioembolization (TriNav Study)#903448ClinicalTrials.gov